Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
<p>Shows the persistence of anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) in the peripheral blood of two out of four patients.</p>
Đã lưu trong:
| Tác giả chính: | |
|---|---|
| Tác giả khác: | , , , , , , , , , , , , |
| Được phát hành: |
2025
|
| Những chủ đề: | |
| Các nhãn: |
Thêm thẻ
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|
| _version_ | 1849927634555764736 |
|---|---|
| author | Ulka N. Vaishampayan (15051039) |
| author2 | Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| author2_role | author author author author author author author author author author author author author |
| author_facet | Ulka N. Vaishampayan (15051039) Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ulka N. Vaishampayan (15051039) Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| dc.date.none.fl_str_mv | 2025-11-25T12:41:19Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30705752 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Figure_S2_from_Phase_II_Trial_of_Pembrolizumab_and_Anti-CD3_x_Anti-HER2_Bispecific_Antibody-Armed_Activated_T_Cells_in_Metastatic_Castration-Resistant_Prostate_Cancer/30705752 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |
| dc.title.none.fl_str_mv | Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Shows the persistence of anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) in the peripheral blood of two out of four patients.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_e3af83da0b96d52606c05c00a44904d1 |
| identifier_str_mv | 10.1158/1078-0432.30705752 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30705752 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate CancerUlka N. Vaishampayan (15051039)Archana Thakur (15051042)Wei Chen (15051045)Abhinav Deol (15051048)Meera Patel (15051051)Kimberlee Dobson (15051054)Brenda Dickow (15051057)Dana Schalk (15051060)Amy Schienschang (15051063)Sarah Whitaker (15051066)Amanda Polend (15051069)Joseph A. Fontana (411960)Elisabeth I. Heath (15024674)Lawrence G. Lum (15051072)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsPhase II clinical trialsGenitourinary CancersProstate cancerImmunotherapyCellular immunotherapy<p>Shows the persistence of anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) in the peripheral blood of two out of four patients.</p>2025-11-25T12:41:19ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30705752https://figshare.com/articles/figure/Supplementary_Figure_S2_from_Phase_II_Trial_of_Pembrolizumab_and_Anti-CD3_x_Anti-HER2_Bispecific_Antibody-Armed_Activated_T_Cells_in_Metastatic_Castration-Resistant_Prostate_Cancer/30705752CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307057522025-11-25T12:41:19Z |
| spellingShingle | Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Ulka N. Vaishampayan (15051039) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |
| status_str | publishedVersion |
| title | Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_full | Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_fullStr | Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_full_unstemmed | Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_short | Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_sort | Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| topic | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |